ZBH

Business Context and Reporting Period

Company: Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: A global leader in orthopaedic and dental reconstructive implants, spinal implants, trauma products, and related surgical products. Operations are managed through three geographic segments: Americas (57% of sales), Europe (29%), and Asia Pacific (14%).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6% year-over-year, driven by a 3% increase in volume/mix and a 3% positive impact from foreign exchange rates. Selling prices were flat globally.
• Profitability: Operating profit decreased 3% to $1.09 billion, primarily due to lower gross margins and increased operating expenses. However, Net Earnings increased 10% due to a lower effective tax rate (24.3% vs. 31.6%) and higher interest income.
• Acquisition: Acquired Abbott Spine in October 2008 for approximately $360 million, adding critical mass to the spine product category. This resulted in $48.7 million in acquisition and integration costs, including $38.5 million in in-process R&D expense.
• Debt: Long-term debt increased significantly from $104.3 million to $460.1 million, largely to fund the Abbott Spine acquisition and stock repurchases.

Guidance, Outlook, Risks, and Unusual Items

Unusual Items and Disruptions

• Durom Cup Suspension: In July 2008, the company suspended marketing of the Durom Acetabular Component in the U.S. to update labeling and training. A provision of $69.0 million was recorded for patient claims related to revision surgeries. This event negatively impacted hip sales and delayed entry into the U.S. hip resurfacing market.
• OSP Product Recalls: Voluntary recalls and production suspensions of Orthopaedic Surgical Products (OSP) at the Dover, Ohio facility adversely impacted 2008 OSP revenues by approximately $70 million and diluted EPS by $0.18.
• Compliance Costs: Costs related to the Deferred Prosecution Agreement (DPA), Corporate Integrity Agreement (CIA), and enhanced global compliance initiatives totaled approximately $60 million in 2008.

Outlook and Guidance

• 2009 Expectations: Management expects sales growth to be slower than the market in the near term due to ongoing customer losses from 2008 disruptions. Share loss is expected to stabilize by year-end 2009.
• Operating Expenses: Total operating expenses are expected to decrease modestly in 2009 due to savings on compliance fees and one-time claims, partially offset by increased spending on product development and quality systems.
• Market Risks: Risks include the global economic crisis affecting elective procedures, currency exchange rate fluctuations (stronger dollar expected to negatively impact sales by ~4% in 2009), and potential further litigation or regulatory actions.

Investor Verification Checklist

• Product Liability Exposure: Verify the sufficiency of the $69.0 million provision for Durom Cup claims and monitor for additional litigation filings.
• Market Share Recovery: Assess the timeline for recovering market share lost in knee and hip segments due to the 2008 product suspensions and recalls.
• Compliance Oversight: Monitor the status of the Deferred Prosecution Agreement (DPA) and Corporate Integrity Agreement (CIA) to ensure no material breaches occur that could lead to exclusion from federal healthcare programs.
• Abbott Spine Integration: Evaluate the integration progress and revenue contribution of the Abbott Spine acquisition in 2009.
• Inventory Levels: Review inventory days (344 days at year-end) to ensure write-downs do not increase further due to the OSP disruptions and lower-than-forecasted sales.